Rankings
▼
Calendar
BIIB FY 2018 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena
BIIB
Biogen Inc.
$28B
FY 2018 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$13.5B
+9.6% YoY
Gross Profit
$11.6B
86.5% margin
Operating Income
$5.9B
43.8% margin
Net Income
$4.4B
32.9% margin
EPS (Diluted)
$21.58
Cash Flow
Operating Cash Flow
$6.2B
Free Cash Flow
$5.3B
Stock-Based Comp.
$158M
Balance Sheet
Total Assets
$25.3B
Total Liabilities
$12.3B
Stockholders' Equity
$13.0B
Cash & Equivalents
$1.2B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13.5B
$12.3B
+9.6%
Gross Profit
$11.6B
$10.6B
+9.3%
Operating Income
$5.9B
$5.3B
+10.2%
Net Income
$4.4B
$2.5B
+74.5%
← Q4 2017
All Quarters
Q1 2018 →